We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

5803:TSEFujikura Ltd Analysis

Data as of 2026-06-17 - not real-time

¥4,729.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Fujikura Ltd. is trading at ¥4,729, a level that sits far above its DCF‑derived fair value of roughly ¥894, indicating a substantial valuation premium. The stock’s forward P/E of 15.6 and current P/E of 49.9 dwarf the industry average of 31.2, while the price‑to‑book ratio of 13.97 further underscores the overvalued stance. Fundamentally, the company posts robust 22% revenue growth, a solid ROE of 31.5%, and a healthy cash position that comfortably covers its debt, suggesting underlying strength. However, the market exhibits extreme short‑term volatility (126% 30‑day) and a high beta of 1.43, reflecting sensitivity to broader market swings. Technical signals are mixed: the RSI sits at a neutral 47.6, the 20‑day SMA (¥4,713) aligns closely with price, and a bullish MACD histogram (+19) hints at modest upside momentum, yet volume is on a decreasing trend. Recent governance moves—including a new restricted‑stock compensation plan and an auditor transition to Deloitte—signal a push for stronger performance oversight. Analyst consensus remains strongly positive (strong_buy) with a median target of ¥5,500, implying a modest upside of about 22% from current levels. Balancing the solid fundamentals against the pronounced overvaluation and heightened risk, the outlook favours caution in the near term while recognising the company’s long‑term resilience.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Current price far exceeds DCF fair value
  • High short‑term volatility and beta
  • Neutral RSI with decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong revenue growth and ROE
  • Forward earnings multiple suggests potential earnings upside
  • Governance enhancements improving performance focus

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustainable dividend payout and solid cash flow
  • Diversified global exposure balances geographic risk
  • Fundamental strength may support price correction over time

Key Metrics & Analysis

Financial Health

Revenue Growth22.00%
Profit Margin13.29%
P/E Ratio49.9
ROE31.51%
ROA13.11%
Debt/Equity17.13
P/B Ratio14.0
Op. Cash Flow¥132.9B
Free Cash Flow¥43.1B
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI47.6
Support¥3,888.00
Resistance¥5,653.00
MA 20¥4,713.35
MA 50¥5,367.28
MA 200¥3,695.16
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value¥894.10
Target Price¥5,799.17
Upside/Downside22.63%
GradeOvervalued
TypeGrowth
Dividend Yield0.80%

Risk Assessment

Beta1.43
Volatility126.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.